Direct Cost of Parkinson’s Disease: A Real-World Data Study of Second-Line Therapies

Elisa Gomez-Inhiesto,1 María Teresa Acaiturri-Ayesta,1 Iker Ustarroz-Aguirre,1 Diana Camahuali,2 Maider Urtaran-Laresgoiti,2 Marisol Basabe-Aldecoa,2 Roberto Nuño-Solinis,2 and Elena Urizar2

1Dirección Económico-Financiera, Hospital Universitario Cruces—OSI Ezkerraldea Enkarterri Cruces, Barakaldo, Biscay, Spain
2Deusto Business School Health, University of Deusto, Bilbao, Spain

Correspondence should be addressed to Elisa Gomez-Inhiesto; mariaelisa.gomezinhiesto@osakidetza.eus and Elena Urizar; elena.urizar@deusto.es

Received 12 November 2019; Revised 27 January 2020; Accepted 6 April 2020; Published 12 May 2020

Academic Editor: Giovanni Mirabella

Copyright © 2020 Elisa Gomez-Inhiesto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Parkinson’s disease is one of the main reasons for neurological consultation in Spain. Due to the nature of the disease, it impacts patients, families, and caregivers. Parkinson’s disease is a degenerative disease with no cure, although second-line therapies have recently improved the quality of life of patients in advanced stages. The aim of this study was to analyse the costs of the following therapies: deep brain stimulation (DBS), continuous duodenal levodopa/carbidopa infusion (CDLCI), and continuous subcutaneous apomorphine infusion (CSAI). The methodology used was based on real-world data obtained from an integrated healthcare organization in the Basque Country from 2016 to 2018. This bottom-up retrospective approach only took into account the healthcare perspective. The results revealed the annual cost over 3 years and the projected cost for an additional 2 years. The total costs for 5 years of treatment were as follows: €53,217 for DBS, €208,163 for CDLCI, and €170,591 for CSAI. These costs are in line with those found in the available literature on the subject. Additionally, the analysis provided details of the different costs incurred during intervention with the therapies and compared the costs to those reported in other studies.

1. Introduction

Parkinson’s disease (PD) is the second most common degenerative disease of the nervous system after Alzheimer’s disease. The incidence is 21/100,000; the disease mainly affects older adults, and its prevalence increases with age. In Spain, the incidence is 1.9/1,000, making it the second most common cause of neurological consultation. Due to the nature of the disease, it is considered to be underdiagnosed [1–3].

PD can be associated with nonmodifiable risk factors such as age and gender. In men, the prevalence and incidence can be 1.5 to 2 times higher, respectively, than those in women. Other risk factors include family history and exposure to agricultural pesticides and some drugs, such as lithium and antipsychotics, while genetic risk factors have also been described [3, 4].

The initiation and development of PD and most of the motor symptoms of the disease are due to the progressive loss of substantia nigra (SN) neurons in the dopaminergic pathway. The most characteristic motor symptoms of PD, such as resting tremor, muscle stiffness, gait disturbances, and micrographia, are induced when the dopaminergic pathway is affected. Nonmotor symptoms may include pain, fatigue, sexual dysfunction, loss of autonomy, cognitive impairment, and psychiatric symptoms [1, 5–7].

Disease progression is gradual and slow. As there is no cure for PD, treatment is symptomatic and focuses on improving quality of life. In the early stages, therapeutic strategies involve orally administered drugs and physical and nutritional therapy. The second-line therapies used in advanced stages can be more invasive. These include deep brain stimulation (DBS), continuous duodenal levodopa/
Parkinson’s Disease

carbopold infusion (CDLCI), and continuous subcutaneous
apomorphine infusion (CSAI), which are the focus of this
study. There is no consensus regarding the causes of ad-
vanced PD. However, many researchers agree that it is linked
to refractory symptoms following conventional treatment
and involves alternating periods when motor symptoms
respond to therapeutics and periods when they do not. In
addition, dyskinesia is moderate to severe in advanced PD
and is accompanied by a loss of autonomy and cognitive
disability.

As Parkinson’s disease is a chronic, progressive, and
irreversible condition, it has a great social impact. The
quality of life of patients, families, and caregivers is ex-
tremely affected due to the increasing care required as the
disease progresses and the resulting high expenses. In recent
years, the survival rates of PD have improved due to pop-
ulation ageing, technological advances, and an improve-
mant in social and health benefits in developed countries. Thus,
patients require more years of care, and costs have conse-
quently risen, presenting a challenge to the sustainability of
the healthcare system in the long term [2, 5, 6].

Reviews by Boloventa et al. [8] and Rodríguez-Blázquez
et al. [9] summarized cost studies of the application of di-
verse methodologies for PD, but there have been very few
studies based on real-world data (RWD). In this regard, the
importance of this study lies in the source of the information
and the possibility of using the results for better decision-
making. Furthermore, the methodology may be able to be
replicated as it uses reliable data from three therapies for the
treatment of advanced PD.

2. Objective

The purpose of this study is to analyse the cost of the three
main forms of treatment for Parkinson’s disease through
real-world data from an integrated healthcare organization
in the Basque Country in Spain.

3. Methodology

The data for the patient cost information system (PCIS) at the integrated health orga-
nization (IHO) known as Ezkerraldea Enkarterri Cruces. At
this organization, a model of cost per patient was designed
and implemented using a bottom-up methodology that
connects all sources of information generated in clinical
practice with economic information. This system provides
individualized cost per patient in detail, allowing the
traceability of all clinical care, including primary and spe-
cialist care. This information system allows for the analysis of
costs based on diagnosis, patient, or procedure and includes
all resources consumed (hospitalization, operating rooms,
prostheses, pharmacy, consultations, laboratory, radiology,
etc.). The PCIS enables the study of the variability of costs
derived from clinical practice, as well as differences in
consumption between patients.

This is a retrospective study that analysed direct costs
from a healthcare perspective (not social costs). The data
were from the period from 2016 to 2018 and from all
patients with a diagnosis of PD who received one of the
following three forms of treatment: deep brain stimula-
tion (DBS), continuous duodenal/carbidopa infusion
(CDLCI), or continuous subcutaneous apo-
morphine infusion (CSAI). In addition, all the healthcare
costs for each patient, including hospital care, primary
care, and outpatient pharmacy costs, were taken into
account. Patients with PD go through different treatment
phases. The PCIS enabled the identification of patients
who started treatment, continuers, and patients who
 discontinued treatment in each year of the study. This
approach allowed us to take into account the real costs of
the analysis. Patient transition data were included for
calculation purposes (Figure 1).

After determining the average annual cost of these forms
of treatment, the information was extrapolated two years
forward. This allows us to compare the full course of
treatment, including the battery replacement required by the
neurostimulator device in the fifth year of DBS.

4. Results

A total of 938 patients diagnosed with PD were treated from
2016 to 2018 and incurred a total cost of 11,003.856 euros at
the IHO. A total of 105 patients from this initial group
received one of the three types of treatment evaluated in this
study; 57% of patients were treated with DBS, 25.7% with
CDLCI, and 17.3% with CSAI.

4.1. Deep Brain Stimulation (DBS).

For DBS treatment, two
specific times at which costs varied were identified. In the
first year of treatment, physicians implanted electrodes in a
specific area of the brain and the impulse generator device in
the thorax. In patients treated at this organization, the
impulse generator batteries were replaced 4.8 years following
implantation. There was a total of 60 patients, and Table 1
shows the number of patients that underwent the implan-
tation and replacement procedures.

During the first year of treatment, when the neuro-
stimulator device was implanted, the average annual cost per
patient was 32,363 euros (standard deviation of 5,067 euros).
Fifty percent of this amount corresponded to the cost of the
device (16,181.5 euros), 33% to the cost of the operating
room (10,679.79 euros), 12% to the cost of hospitalization
(3,883.56 euros), 3% to outpatient pharmaceutical products
(970.89 euros), and 2% to in-hospital consultations (647.26
euros).

The average annual cost per patient in successive years
after implantation was 1,295 euros (standard deviation of
1,395 euros). Thirty-nine percent of this amount corre-
sponded to outpatient pharmaceutical products (505.05
euros), 34% to in-hospital consultations (440.30 euros), 9%
to hospitalization (116.55 euros), and 4% to emergency room
care (51.80 euros) (Figure 2). For the year when the device
battery was replaced, the average annual cost per patient was
16,969 euros (standard deviation of 2,055 euros). Table 2
shows the average cost of treating a patient receiving DBS
over a five-year period.
4.2. Continuous Duodenal Levodopa/Carbidopa Infusion (CDLCI). Twenty-seven patients received CDLCI treatment from 2016 to 2018. The average cost over the three years was 50,554 euros (standard deviation of 39,074 euros) per patient. Seventy-two percent of the cost was for in-hospital drugs (36,398.88 euros), 12% was for hospitalization (6,066.48 euros), and 6% was for outpatient pharmaceutical products (3,033.24 euros).

The average annual cost of infusion pump implantation was 23,212 euros (13,000 euros standard deviation), and it was determined that levodopa/carbidopa accounted for between 82 and 93% of the cost of the entire treatment. Table 3 shows the details for the period from 2016 to 2018. The average accumulated cost over three years was 125,783 euros (standard deviation of 1,639 euros), and 107,748 euros corresponded to the cost of levodopa/carbidopa.

4.3. Continuous Subcutaneous Apomorphine Infusion (CSAI). At the organization in which this study was conducted, 18 patients received CSAI treatment during the period from 2016 to 2018. The average cost per patient accumulated over three years was 50,554 euros (standard deviation of 39,074 euros) per patient. Seventy-two percent of the cost was for in-hospital drugs (36,398.88 euros), 12% was for hospitalization (6,066.48 euros), and 6% was for outpatient pharmaceutical products (3,033.24 euros).

Table 4 shows the five-year costs of patients treated with levodopa/carbidopa, allowing comparisons of the cost of the disease for patients treated with the different therapies.

4.4. Comparative Analysis. Figure 3 shows the cost comparison per patient over a 5-year period for each type of treatment.

5. Discussion

A review of the most recent literature in this field revealed studies that support the methodology we used [8–10]. Analysing costs using RWD is relevant because a prevalence is evaluated throughout the study period. Such analyses are performed once diagnosis has been established and all direct costs have been identified. Likewise, when patients have a long survival time, retrospective studies, such as the present study, are highly suitable. This is consistent with other studies that have used the same approach [9].

Other research has shown the high costs of PD. Rodriguez-Blázquez et al. analysed 70 articles related to this topic, gathering information from countries such as Belgium, Finland, and the United States and showed that healthcare costs represent the greatest burden and increase as the disease progresses. Similarly, it has been observed that social costs are lower in the early stages when the autonomy of the patient is preserved [9, 10].

As found in the analysis of each treatment, DBS has a high initial cost due to associated procedures and controls, although the costs of the adjuvant drugs over the subsequent years are lower. According to our results, the first year accounts for 60% of the total cost of the five years of treatment (Table 2), whereas other studies have found that this figure is only 32.2%. These differences may be due to the difference in methodologies and resources considered in the analysis [10, 11]. In the United States, it has been shown that DBS costs USD $37,481 per patient during the first year, which is similar to the figure obtained in the present study. Likewise, in Germany, it has been found that the cost decreases markedly after the first year, costing 2,689 euros per patient [9]. In our study, it was found that after an initial investment of 32,363 euros, the cost over the following years was 1,295 euros.

Table 6 shows the costs at 3 and 5 years for patients treated with apomorphine, allowing comparisons of the cost of the disease.
per year, which may have increased as the symptoms of PD worsened.

The results obtained are in line with the available literature. In 2013, Valldeoriola et al. carried out a five-year comparative analysis of healthcare costs associated with the same three therapeutic options. However, they estimated costs via questionnaires of experts and noted that the mean cumulative 5-year cost per patient was significantly lower for DBS (88,014 euros) than for CSAI (141,393 euros) or CDLCI (233,986 euros).

The data analysed in the present study are accurate, as the study was based on RWD. Likewise, the literature has shown that the differences in results between various studies are due to specific contextual factors and the features of each health system. Costs increase at advanced stages of the disease, and refractoriness causes less effectiveness in controlling symptoms and, in many cases, abandonment or discontinuation of treatment [13, 14]. In a retrospective study using a bottom-up methodology, the cost increased with each year of the disease and in some periods doubled from USD $4,317 to USD $9,658. It is important to note these variations between the different studies to ensure more precise and comparable designs. [15].

### Table 1: Patients treated with DBS from 2016 to 2018.

| Year | 2016 | 2017 | 2018 |
|------|------|------|------|
| Neurostimulator device implantation | 16 patients | 19 patients | 18 patients |
| Battery replacement | 0 patients | 5 patients | 2 patients |

### Table 2: Total cost of DBS over five years of treatment.

| Year | Year 1 (implantation) | Year 2 | Year 3 | Year 4 | Year 5 (battery change) | Total cost |
|------|-----------------------|--------|--------|--------|-------------------------|------------|
| Average annual cost | €32,363 | €1,295 | €1,295 | €1,295 | €16,969 | €53,217 |

### Table 3: Average annual cost of CDLCI from 2016 to 2018.

| Year | 2016 | 2017 | 2018 |
|------|------|------|------|
| Average annual cost | €43,356 | €42,967 | €41,043 |
| Levodopa/carbidopa average annual cost | €35,368 | €39,917 | €38,211 |
| % of total cost related to levodopa/carbidopa | 82% | 93% | 93% |

### Table 4: Total cost of CDLCI over five years of treatment.

| Year | Years 1–3 | Year 4 | Year 5 | Total cost |
|------|-----------|--------|--------|------------|
| Average cost | €125,783 | €41,190 | €41,190 | €208,163 |

### Table 5: Cost of CSAI for one patient.

| Year | 2016 | 2017 | 2018 |
|------|------|------|------|
| Average annual cost | €34,388 | €31,536 | €36,431 |
| Apomorphine average annual cost | €25,191 | €22,459 | €27,619 |
| % of total cost related to apomorphine | 73% | 71% | 76% |

As costs vary by country according to each health system’s characteristics and the availability of resources [15], economic assessments have become an integral part of decision-making for clinicians and public policy makers [13]. Information on costs is needed not only from a general standpoint but also to ensure that the aggregation of data from different sources can improve the efficiency of the systems [13, 16].

The limitations of most studies involve incomplete descriptions of the methods used, the source of information, the subjectivity of some measures in the results, and different timelines and methodologies [11]. The main limitation of the study carried out in this IHO was the small number of individuals included. Furthermore, this study was designed according to patients’ traceability. Therefore, certain inputs that cannot be traced or assigned at the individual level were not included, although these costs can be deemed minimal.
6. Conclusions

The analysis enabled us to ascertain the details of the costs incurred by treatment with DBS, CDLCI, and CSAI and compare them to the results found in the literature on the subject. DBS is one of the least expensive treatments over a five-year period. For DBS, the largest costs are incurred when the implantation procedure is performed and when the battery is changed. The costs of CDLCI and CSAI are similar to those observed in Spain in the study by Valderiola et al. Compared with studies from other countries, our results are different but provided mostly similar findings.

During the review of the literature and comparisons of the results, we found that it is important to take into account the nuances that can be drawn from the study framework. PD has a high cost burden from all perspectives (patient, payer, provider, and social) that increases as the disease progresses. Due to current trends that have led to an increase in life expectancy, greater survival rates, and an increase in the disease period of PD, it is imperative to understand and clarify the costs of treating advanced PD with second-line therapies.

Ascertaining the cost per patient over a complete cycle or period of care enables the determination of the cost incurred by patients for each type of intervention. Furthermore, it allows an understanding of the relationship between the results and the resources necessary to obtain such results. For this reason, a cost-per-patient system provides relevant information for decision-making about alternative forms of treatment.

The reviewed studies on costs associated with this pathology applied different methodologies and addressed the issue from different approaches. Some did not specify whether the patients were in an early or advanced stage, which caused significant variations in costs significant and made costs more difficult to compare. This study highlights the types of treatment analysed and describes how the data obtained from the patients included in the study were exploited.

Currently, measuring the concept of “value” in healthcare, which includes maximizing outcomes that are important to people at the lowest possible cost, is increasingly seen as being the key for transforming healthcare delivery towards more efficient and sustainable models. The challenge involves implementing value-based healthcare (VBHC) in practice, both at the clinical and organizational level, and aligning this effort with integrated care and population health management perspectives. It is necessary to improve methodologies of cost analysis [17] and transform data into powerful patient-level information. However, there is a far greater focus on measuring health outcomes than measuring costs. Therefore, this research intended to fill this gap by providing a comparative RWD cost analysis of second-line therapies for patients with PD.

Data Availability

The data are not public but available on request to the research team.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] DynaMed, “IPSWICH (MA): EBSCO information services,” 1995, https://www.dynamed.com/topics/dmp~AN~T115172 Record No. T115172.
[2] J. Benito León, “Epidemiología de la enfermedad de Parkinson en España y su contextualización mundial,” Revista de Neurología, vol. 66, no. 4, pp. 125–127, 2018.
[3] P. Martínez-Martin, J. Kulisevsky, P. Mir, E. Tolosa, P. García-Delgado, and M.-R. Luquin, “Validation of a simple screening tool for early diagnosis of advanced Parkinson’s disease in daily practice: the CDEPA questionnaire,” NPJ Parkinson’s Disease, vol. 4, no. 1, 2018.
[4] M. Barkhuizen, D. G. Anderson, and A. F. Grobler, “Advances in GBA-associated Parkinson’s disease—pathology, presentation and therapies,” Neurochemistry International, vol. 93, pp. 6–25, 2016.
[5] J. Lowin, K. Sail, R. Baj et al., “The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinsonian disease,” Journal of Medical Economics, vol. 20, no. 11, pp. 1207–1215, 2017.
[6] J. Waldthaler and L. Timmermann, “Neuez diagnostik und therapie des idiopathischen Parkinson-syndroms,” Fortschritte der Neurologie—Psychiatrie, vol. 87, no. 8, pp. 445–461, 2019.
[7] F. Diás, F. Dias, R. Balestri, and S. Mella, “Doença de Parkinson: aspectos fisiopatológicos e terapêuticos,” Revista Saúde e Pesquisa, vol. 3, no. 2, pp. 221–228, 2010.
[8] T. Bovolenta, S. de Azevedo Silva, R. Arb Saba, V. Borges, H. Ferraz, and A. Felicio, “Systematic review and critical analysis of cost studies associated with Parkinson’s disease,” Parkinson’s Disease, vol. 2017, Article ID 3410946, 11 pages, 2017.
[9] C. Rodríguez-Blázquez, M. J. Forjaz, L. Lizán, S. Paz, and P. Martínez-Martín, “Estimating the direct and indirect costs
associated with Parkinson’s disease,” Expert Review of Pharmacoconomics & Outcomes Research, vol. 15, no. 6, pp. 889–911, 2015.

[10] F. Valldeoriola, J. Puig-Junoy, R. Puig-Peiró, and Workgroup of the SCOPE study, “Cost analysis of the treatments for patients with advanced Parkinson’s disease: SCOPE study,” Journal of Medical Economics, vol. 16, no. 2, pp. 191–201, 2012.

[11] J. E. Becerra, O. Zorro, R. Ruiz-Gaviria et al., “Economic analysis of deep brain stimulation in Parkinson disease: systematic review of the literature,” World Neurosurgery, vol. 93, pp. 44–49, 2016.

[12] E. Walter and P. Odin, “Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s disease in the UK and Germany,” Journal of Medical Economics, vol. 18, no. 2, pp. 155–165, 2014.

[13] Y. J. Zhao, L. C. S. Tan, W. L. Au et al., “Estimating the lifetime economic burden of Parkinson’s disease in Singapore,” European Journal of Neurology, vol. 20, no. 2, pp. 368–374, 2012.

[14] S. von Campenhausen, Y. Winter, A. Rodrigues e Silva et al., “Costs of illness and care in Parkinson’s disease: an evaluation in six countries,” European Neuropsychopharmacology, vol. 21, no. 2, pp. 180–191, 2011.

[15] T. Bovolenta, S. Azevedo Silva, R. A. Saba, V. Borges, H. B. Ferraz, and A. Felicio, “Average annual cost of Parkinson’s disease in São Paulo, Brazil, with a focus on disease-related motor symptoms,” Clinical Interventions in Aging, vol. 12, pp. 2095–2108, 2017.

[16] Y. Winter, S. von Campenhausen, H. Brozova et al., “Costs of Parkinson’s disease in eastern Europe: a Czech cohort study,” Parkinsonism & Related Disorders, vol. 16, no. 1, pp. 51–56, 2010.

[17] R. S. Kaplan and M. E. Porter, “How to solve the cost crisis in health care,” Harvard Business Review, vol. 89, no. 9, pp. 56–61, 2011.